PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 9, 2026Biomedical Letters0 citations

Comparative modeling and in silico identification of drug target sites in RASSF3

Key Points

  • This research aims to model the 3D structure of RASSF3 and identify potential drug target sites.
  • Predicted RASSF3 structure using homology modeling with MODELLER and tools like I-TASSER.
  • Evaluated model accuracy with ERRAT, PROCHECK, and Rampage.
  • Identified binding pockets using the CASTp server.
  • Conducted molecular docking with AutoDock Vina and AutoDock4.
  • The selected model showed promising accuracy for further analysis.
  • Binding energies for ligands ANP and GNP were -5.7 and -5.3 Kcal/mol.
  • RASSF3's binding domains and interactions were characterized, indicating its potential as a drug target.

Abstract

RASSF3 is a gene that encodes a protein with tumor-suppressive properties, primarily by promoting apoptosis and regulating the cell cycle. It plays a significant role in inhibiting cancer progression. In this study, the 3D structure of RASSF3 was predicted using homology modeling. MODELLER (v10.4) and online tools such as I-TASSER, Swiss-Model, and MODWEB were employed for model generation. The structural models were evaluated for accuracy using tools including ERRAT, PROCHECK, and Rampage. The most reliable model, based on validation, was selected for molecular docking studies. Binding pockets of RASSF3 were identified using the CASTp server. Molecular docking was carried out using AutoDock Vina and AutoDock4 to investigate the interaction between RASSF3 and two selected ligands: ANP and GNP. These compounds demonstrated the lowest binding energies of -5.7 and -5.3 Kcal/mol respectively and the highest binding affinities within the top-ranked binding site. Identification of these binding domains and ligand interactions is critical for understanding the functional behavior of RASSF3 and its role in cancer inhibition. The predicted binding pockets and docking results suggest that RASSF3 could serve as a promising target in anticancer drug discovery.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

A 2025 study studied this question.

synapsesocial.com/papers/69897a14f0ec2af6756e862ahttps://doi.org/10.47262/bl/9.1.20230503
Ask AI
Helpful
Bookmark
Share
View Full Paper